Drugs / Calcium DTPA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05359835 | Apr 2023 → Sep 2024 | — | Stanford University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02947022 | Oct 2016 → Jan 2017 | arthropathy, cognitive disorder, headache disorder, hyperpigmentation of the skin | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00001575 Background | Apr 1997 → Nov 2013 | Hodgkins lymphoma, non-Hodgkin lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Calcium-DTPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001575 ↗ |
| Route | Intravenous | “Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body” NCT00001575 ↗ |